Clinical trials: Vinorelbine
Lung Cancer
Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00054197
- Testing
- gemcitabine hydrochloride, paclitaxel poliglumex, vinorelbine tartrate
- Where
- 10 sites in United States
- Sponsor
- CTI BioPharma
Breast Cancer
Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006682
- Testing
- docetaxel, vinorelbine ditartrate
- Where
- 2 sites in United States
- Sponsor
- Medstar Health Research Institute
Lymphoma
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00003963
- Testing
- rituximab, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer
Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop tumor cells from dividing so they…
- Trial name
- NCT00075673
- Testing
- celecoxib, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer
Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer
The primary objective of this study is to compare progression-free survival (PFS) of patients with metastatic Luminal B2 breast cancer subtype randomised to treatment with Trastuzumab Combined With Chemotherapy or Endocrine…
- Trial name
- SYSUCC-002 (NCT01950182)
- Testing
- Endocrine therapy combined with trastuzumab, Chemotherapy combined with trastuzumab
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Sun Yat-sen University
HER2 Positive Breast Cancer
A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer
Evaluating the Efficacy of Lapatinib in Combination With Chemotherapy in Patients With Trastuzumab-refractory Metastatic HER2-positive Breast Cancer.
- Trial name
- NCT02362958
- Testing
- lapatinib and capecitabine or vinorelbine
- Where
- China
- Volunteers
- 159 people
- Sponsor
- Sun Yat-sen University
Hormone Receptor Positive Advanced Breast Cancer
A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer
This is a single-center phase II study designed to evaluated the efficacy and safety of fulvestrant in combination with oral vinorelbine in hormone receptor-positive advanced breast cancer
- Trial name
- NCT03939871
- Testing
- fluvestrant + oral vinorelbine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese Academy of Medical Sciences
Carcinoma, Non-Small-Cell Lung, Immune-Related Adverse Events
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
The objective of our study is to assess the risk of immune-related adverse events associated with PD-1 inhibitors use compared to standard chemotherapy use in patients with non small cell lung cancer, using nationwide healthcare…
- Trial name
- NCT04115410
- Testing
- PD-1 inhibitor, Chemotherapy Drugs, Cancer
- Volunteers
- 4,724 people
- Sponsor
- Sungkyunkwan University
Peripheral T-Cell Lymphoma
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
This study examines the use of denileukin diftitox (Ontak) for patients with peripheral T-cell lymphoma who are candidates for autologous stem cell transplants.
- Trial name
- NCT00632827
- Testing
- Gemcitabine, Navelbine, Doxorubicin Hydrochloride Liposome Injection
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Francisco
Lung Cancer
Vinorelbine + Cisplatin or No Further Therapy in Non-small Cell Lung Cancer That Has Been Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if combination chemotherapy is more effective than no further treatment for non-small…
- Trial name
- NCT00002583
- Testing
- cisplatin, vinorelbine ditartrate
- Where
- 155 sites in United States, Canada
- Volunteers
- 482 people
- Sponsor
- NCIC Clinical Trials Group
Diffuse Large B-cell Lymphoma
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
This is a prospective phase II clinical trial to observe the efficacy and safety of Chidamide combined with VDDT(vinorelbine，liposomal doxorubicin，dexamethasone and thalidomide) in relapsed and refractory patients with diffuse…
- Trial name
- NCT02733380
- Testing
- Chidamide, Vinorelbine, Liposomal Doxorubicin or mitoxantrone
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer
NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy
This is a prospective, randomized, open-lable phase III clinical trial evaluating the effectiveness and safety of vinorelbine plus capecitabine as adjuvant treatment for non-pCR Luminal B breast cancer patients after standard…
- Trial name
- NCT04307147
- Testing
- Capecitabine, Vinorelbine
- Where
- China
- Volunteers
- 316 people
- Sponsor
- Fudan University
Lung Neoplasm Malignant
Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer
This is an open-label, multi-center clinical trial, aims to evaluate the efficacy and safety of combination of oral Navelbine and Cisplatin followed by metronomic oral Navelbine in Patients with advanced Non-Small Cell Lung…
- Trial name
- NCT02985203
- Testing
- Vinorelbine Oral
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Guangdong Association of Clinical Trials
Breast Cancer
A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy
This study aims to evaluate vinorelbine plus capecitabine combined with trastuzumab versus trastuzumab alone as the adjuvant Treatment of HER2 positive patients following neoadjuvant chemotherapy
- Trial name
- NCT04302441
- Testing
- Vinorelbine, Capecitabine
- Where
- China
- Volunteers
- 550 people
- Sponsor
- Fudan University
Non-small Cell Lung Cancer
Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation
Activating somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have been characterized in a subset of patients with advanced NSCLC.The EGFR mutation rate was 30% in Chinese Non-small Cell…
- Trial name
- ADJUVANT (NCT01405079)
- Testing
- Gefitinib, Vinorelbine+Cisplatin
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Guangdong Association of Clinical Trials
Advanced Non Small Cell Lung Cancer
Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer
The purpose of this study is to assess the safety and effectiveness of Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Posterior Advanced Non-small Cell Lung Cancer
- Trial name
- NCT03652857
- Testing
- Apatinib Combined With Vinorelbine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yongchang Zhang
Lymphoma, Non-Hodgkin
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models.
- Trial name
- NCT00088530
- Testing
- pixantrone, cyclophosphamide, vincristine, rituximab, prednisone, Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab
- Where
- 99 sites in United States, Argentina and 18 more
- Volunteers
- 140 people
- Sponsor
- CTI BioPharma
Non Small Cell Lung Cancer
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Determine whether viagenpumatucel-L combined with low-dose cyclophosphamide prolongs survival in patients with NSCLC who failed 2 or 3 prior lines of therapy for incurable or metastatic disease compared with chemotherapy alone.
- Trial name
- NCT02117024
- Testing
- Viagenpumatucel-L, Metronomic Cyclophosphamide, Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)
- Where
- 16 sites in United States
- Volunteers
- 66 people
- Sponsor
- Heat Biologics
Locally Advanced/ Metastatic NSCLC
Observational Study With Metronomic Oral Vinorelbine in Elderly Patients With Locally Advanced / Metastatic Non-small-cell Lung Cancer (NSCLC)
Vinorelbine is the first line reference drug in the elderly patient with locally advanced / metastatic non-small-cell lung cancer (NSCLC).
- Trial name
- VINORELBINA (NCT04208854)
- Testing
- Vinorelbine
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- International Group of Endovascular Oncology
Non-small Cell Lung Cancer Metastatic
Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors
After progression to previous PD-1/L1 inhibitors (pembrolizumab, nivolumab, or atezolizumab), physicians' choice chemotherapy plus pembolizumab (or placebo) will be administered (3 weeks per cycle) until disease progression or…
- Trial name
- NCT03656094
- Testing
- Pembrolizumab plus chemotherapy
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- Samsung Medical Center